DOCSLIB.ORG

Pharmaceutical Appendix to the Tariff Schedule 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 ACOXATRINE 748-44-7 ACAPRAZINE 55485-20-6 ACREOZAST 123548-56-1 ACARBOSE 56180-94-0 ACRIDOREX 47487-22-9 ACEBROCHOL 514-50-1 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEBURIC ACID 26976-72-7 ACRIHELLIN 67696-82-6 ACEBUTOLOL 37517-30-9 ACRISORCIN 7527-91-5 ACECAINIDE 32795-44-1 ACRIVASTINE 87848-99-5 ACECARBROMAL 77-66-7 ACROCINONIDE 28971-58-6 ACECLIDINE 827-61-2 ACRONINE 7008-42-6 ACECLOFENAC 89796-99-6 ACTAGARDIN ACEDAPSONE 77-46-3 ACTAPLANIN 37305-75-2 ACEDIASULFONE SODIUM 127-60-6 ACTARIT 18699-02-0 ACEDOBEN 556-08-1 ACTINOQUINOL 15301-40-3 ACEFLURANOL 80595-73-9 ACTISOMIDE 96914-39-5 ACEFURTIAMINE 10072-48-7 ACTODIGIN 36983-69-4 ACEFYLLINE CLOFIBROL 70788-27-1 ADAFENOXATE 82168-26-1 ACEFYLLINE PIPERAZINE 18428-63-2 ADALIMUMABUM 331731-18-1 ACEGLATONE 642-83-1 ADAMEXINE 54785-02-3 ACEGLUTAMIDE 2490-97-3 ADAPALENE 106685-40-9 ACEMANNAN 110042-95-0 ADAPROLOL 101479-70-3 ACEMETACIN 53164-05-9 ADARGILEUKINUM ALFA 250710-65-7 ACENEURAMIC ACID 131-48-6 ADATANSERIN 127266-56-2 ACENOCOUMAROL 152-72-7 ADECATUMUMABUM 503605-66-1 ACEPERONE 807-31-8 ADEFOVIR 106941-25-7 ACEPROMAZINE 61-00-7 ADEKALANTUM 227940-00-3 ACEPROMETAZINE 13461-01-3 ADELMIDROL 1675-66-7 ACEQUINOLINE 42465-20-3 ADEMETIONINE 17176-17-9 ACESULFAME 33665-90-6 ADENOSINE PHOSPHATE 61-19-8 ACETAMINOSALOL 118-57-0 ADIBENDAN 100510-33-6 ACETARSOL 97-44-9 ADICILLIN 525-94-0 ACETAZOLAMIDE 59-66-5 ADIMOLOL 78459-19-5 ACETERGAMINE 3031-48-9 ADINAZOLAM 37115-32-5 ACETIAMINE 299-89-8 ADIPHENINE 64-95-9 ACETIROMATE 2260-08-4 ADIPIODONE 606-17-7 ACETOHEXAMIDE 968-81-0 ADITEREN 56066-19-4 ACETOHYDROXAMIC ACID 546-88-3 ADITOPRIM 56066-63-8 ACETOPHENAZINE 2751-68-0 ADOSOPINE 88124-26-9 ACETORPHINE 25333-77-1 ADOZELESIN 110314-48-2 ACETRYPTINE 3551-18-6 ADRAFINIL 63547-13-7 ACETYLCHOLINE CHLORIDE 60-31-1 ADRENALONE 99-45-6 ACETYLCYSTEINE 616-91-1 ADROGOLIDUM 171752-56-0 ACETYLDIGITOXIN 1111-39-3 AFALANINE 2901-75-9 ACETYLLEUCINE 99-15-0 AFELETECANUM 215604-75-4 ACETYLMETHADOL 509-74-0 AFELIMOMAB 156227-98-4 ACEVALTRATE 25161-41-5 AFLOQUALONE 56287-74-2 ACEXAMIC ACID 57-08-9 AFOVIRSEN 151356-08-0 ACICLOVIR 59277-89-3 AFUROLOL 65776-67-2 ACIDUM ARUNDICUM 185517-21-9 AGALSIDASUM ALFA 104138-64-9 ACIDUM CALOXETICUM 135306-78-4 AGALSIDASUM BETA 104138-64-9 ACIDUM CARGLUMICUM 1188-38-1 AGANODINE 86696-87-9 ACIDUM GADOCOLETICUM 280776-87-6 AGLEPRISTONE 124478-60-0 AGOMELATINE 138112-76-2 ALNESPIRONE 138298-79-0 AKLOMIDE 3011-89-0 ALNIDITAN 152317-89-0 ALACEPRIL 74258-86-9 ALONACIC 105292-70-4 ALAFOSFALIN 60668-24-8 ALONIMID 2897-83-8 ALAGEBRIUM CHLORIDUM 341028-37-3 ALORACETAM 119610-26-3 ALAMIFOVIRUM 193681-12-8 ALOSETRON 122852-42-0 ALANINE 56-41-7 ALOVUDINE 25526-93-6 ALANOSINE 5854-93-3 ALOXIPRIN 9014-67-9 ALAPROCLATE 60719-82-6 ALOXISTATIN 88321-09-9 ALATROFLOXACIN 157182-32-6 ALOZAFONE 65899-72-1 ALAZANINE TRICLOFENATE 5779-59-9 ALPERTINE 27076-46-6 ALBACONAZOLUM 187949-02-6 ALPHACETYLMETHADOL 17199-58-5 ALBENDAZOLE 54965-21-8 ALPHAMEPRODINE 468-51-9 ALBENDAZOLE OXIDE 54029-12-8 ALPHAMETHADOL 17199-54-1 ALBIFYLLINE 107767-55-5 ALPHAPRODINE 77-20-3 ALBUTOIN 830-89-7 ALPIDEM 82626-01-5 ALCLOFENAC 22131-79-9 ALPIROPRIDE 81982-32-3 ALCLOMETASONE 67452-97-5 ALPRAFENONE 124316-02-5 ALCLOXA 1317-25-5 ALPRAZOLAM 28981-97-7 ALCURONIUM CHLORIDE 15180-03-7 ALPRENOLOL 13655-52-2 ALDESULFONE SODIUM 144-75-2 ALPROSTADIL 745-65-3 ALDIOXA 5579-81-7 ALRESTATIN 51411-04-2 ALDOSTERONE 52-39-1 ALSACTIDE 34765-96-3 ALEFACEPTUM 222535-22-0 ALTANSERIN 76330-71-7 ALEMCINALUM 150785-53-8 ALTAPIZONE 93277-96-4 ALEMTUZUMABUM 216503-57-0 ALTECONAZOLE 93479-96-0 ALENDRONIC ACID 66376-36-1 ALTEPLASE 105857-23-6 ALENTEMOL 112891-97-1 ALTINICLINUM 179120-92-4 ALEPRIDE 66564-15-6 ALTIZIDE 5588-16-9 ALESTRAMUSTINE 139402-18-9 ALTOQUALINE 121029-11-6 ALEXIDINE 22573-93-9 ALTRENOGEST 850-52-2 ALEXITOL SODIUM 66813-51-2 ALTRETAMINE 645-05-6 ALFACALCIDOL 41294-56-8 ALTUMOMAB 156586-92-4 ALFADEX 10016-20-3 ALUMINIUM CLOFIBRATE 24818-79-9 ALFADOLONE 14107-37-0 ALUSULF 61115-28-4 ALFAPROSTOL 74176-31-1 ALVAMELINUM 120241-31-8 ALFATRADIOLUM 57-91-0 ALVERINE 150-59-4 ALFAXALONE 23930-19-0 ALVIMOPANUM 156053-89-3 ALFENTANIL 71195-58-9 ALVIRCEPT SUDOTOX 137487-62-8 ALFETAMINE 4255-23-6 ALVOCIDIBUM 146426-40-6 ALFIMEPRASUM 259074-76-5 AMADINONE 30781-27-2 ALFUZOSIN 81403-80-7 AMAFOLONE 50588-47-1 ALGELDRATE 1330-44-5 AMANOZINE 537-17-7 ALGESTONE 595-77-7 AMANTADINE 768-94-5 ALGLUCERASE 143003-46-7 AMANTANIUM BROMIDE 58158-77-3 ALGLUCOSIDASUM ALFA 420784-05-0 AMANTOCILLIN 10004-67-8 ALIBENDOL 26750-81-2 AMBAMUSTINE 85754-59-2 ALICAFORSENUM 185229-68-9 AMBASILIDE 83991-25-7 ALICONAZOLE 63824-12-4 AMBAZONE 539-21-9 ALIFEDRINE 78756-61-3 AMBENONIUM CHLORIDE 115-79-7 ALIFLURANE 56689-41-9 AMBENOXAN 2455-84-7 ALILUSEMUM 144506-11-6 AMBICROMIL 58805-38-2 ALIMADOL 52742-40-2 AMBOMYCIN 1402-81-9 ALIMEMAZINE 84-96-8 AMBRISENTANUM 177036-94-1 ALINASTINE 154541-72-7 AMBROXOL 18683-91-5 ALINIDINE 33178-86-8 AMBRUTICIN 58857-02-6 ALIPAMIDE 3184-59-6 AMBUCAINE 119-29-9 ALISKIRENUM 173334-57-1 AMBUCETAMIDE 519-88-0 ALITRETINOINUM 5300-03-8 AMBUSIDE 3754-19-6 ALIZAPRIDE 59338-93-1 AMCINAFAL 3924-70-7 ALLETORPHINE 23758-80-7 AMCINAFIDE 7332-27-6 ALLOBARBITAL 52-43-7 AMCINONIDE 51022-69-6 ALLOCLAMIDE 5486-77-1 AMDOXOVIRUM 145514-04-1 ALLOCUPREIDE SODIUM 5965-40-2 AMEBUCORT 83625-35-8 ALLOMETHADIONE 526-35-2 AMEDALIN 22136-26-1 ALLOPURINOL 315-30-0 AMEDIPLASUM 151912-11-7 ALLYLESTRENOL 432-60-0 AMELOMETASONE 123013-22-9 ALLYLPRODINE 25384-17-2 AMELTOLIDE 787-93-9 ALLYLTHIOUREA 109-57-9 AMELUBANTUM 346735-24-8 ALMADRATE SULFATE 60239-66-9 AMESERGIDE 121588-75-8 ALMAGATE 66827-12-1 AMETANTRONE 64862-96-0 ALMAGODRATE AMEZEPINE 60575-32-8 ALMASILATE 71205-22-6 AMEZINIUM METILSULFATE 30578-37-1 ALMECILLIN 87-09-2 AMFEBUTAMONE 34911-55-2 ALMESTRONE 10448-96-1 AMFECLORAL 5581-35-1 ALMINOPROFEN 39718-89-3 AMFENAC 51579-82-9 ALMITRINE 27469-53-0 AMFEPENTOREX 15686-27-8 ALMOKALANT 123955-10-2 AMFEPRAMONE 90-84-6 ALMOTRIPTAN 154323-57-6 AMFETAMINE 300-62-9 ALMOXATONE 84145-89-1 AMFETAMINIL 17590-01-1 ALMURTIDE 61136-12-7 AMFLUTIZOLE 82114-19-0 Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 AMFOMYCIN 1402-82-0 AMPRENAVIRUM 161814-49-9 AMFONELIC ACID 15180-02-6 AMPROLIUM 121-25-5 AMICARBALIDE 3459-96-9 AMPYRIMINE 5587-93-9 AMICIBONE 23271-63-8 AMPYZINE 5214-29-9 AMICYCLINE 5874-95-3 AMQUINATE 17230-85-2 AMIDANTEL 49745-00-8 AMRINONE 60719-84-8 AMIDAPSONE 3569-77-5 AMRUBICIN 110267-81-7 AMIDEFRINE MESILATE 1421-68-7 AMSACRINE 51264-14-3 AMIFLAMINE 77518-07-1 AMTOLMETIN GUACIL 87344-06-7 AMIFLOVERINE 54063-24-0 AMYLMETACRESOL 1300-94-3 AMIFLOXACIN 86393-37-5 ANAGESTONE 2740-52-5 AMIFOSTINE 20537-88-6 ANAGRELIDE 68475-42-3 AMIGLUMIDUM 119363-62-1 ANAKINRA 143090-92-0 AMIKACIN 37517-28-5 ANARITIDE 95896-08-5 AMIKHELLINE 4439-67-2 ANASTROZOLE 120511-73-1 AMILORIDE 2609-46-3 ANATIBANTUM 209733-45-9 AMINDOCATE 31386-24-0 ANATUMOMABUM MAFENATOXUM (NONE) AMINEPTINE 57574-09-1 ANAXIRONE 77658-97-0 AMINITROZOLE 140-40-9 ANAZOCINE 15378-99-1 AMINOACRIDINE 90-45-9 ANAZOLENE SODIUM 3861-73-2 AMINOCAPROIC ACID 60-32-2 ANCAROLOL 75748-50-4 AMINOETHYL NITRATE 646-02-6 ANCESTIMUM 163545-26-4 AMINOGLUTETHIMIDE 125-84-8 ANCITABINE 31698-14-3 AMINOMETRADINE 642-44-4 ANCRIVIROCUM 370893-06-4 AMINOPHENAZONE 58-15-1 ANCROD 9046-56-4 AMINOPHENAZONE CYCLAMATE 747-30-8 ANDOLAST 132640-22-3 AMINOPHYLLINE 317-34-0 ANDROSTANOLONE 521-18-6 AMINOPROMAZINE 58-37-7 ANECORTAVUM 7753-60-8 AMINOPTERIN SODIUM 58602-66-7 ANGIOTENSIN II 4474-91-3 AMINOQUINOL 10023-54-8 ANGIOTENSINAMIDE 53-73-6 AMINOQUINURIDE 3811-56-1 ANIDOXIME 34297-34-2 AMINOREX 2207-50-3 ANIDULAFUNGINUM 166663-25-8 AMINOTHIAZOLE 96-50-4 ANILAMATE 5591-49-1 AMINOXYTRIPHENE 5585-64-8 ANILERIDINE 144-14-9 AMIODARONE 1951-25-3 ANILOPAM 53716-46-4 AMIPERONE 1580-71-8 ANIPAMIL 83200-10-6 AMIPHENAZOLE 490-55-1 ANIRACETAM 72432-10-1 AMIPIZONE 69635-63-8 ANIROLAC 66635-85-6 AMIPRILOSE 56824-20-5 ANISACRIL 5129-14-6 AMIQUINSIN 13425-92-8 ANISINDIONE 117-37-3 AMISOMETRADINE 550-28-7 ANISOPIROL
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Identificación Computacional De Nuevos Compuestos Líderes Con Actividad Analgésica

    Identificación Computacional De Nuevos Compuestos Líderes Con Actividad Analgésica

    IDENTIFICACIÓN COMPUTACIONAL DE NUEVOS COMPUESTOS LÍDERES CON ACTIVIDAD ANALGÉSICA Autor: Earmin Shangoo. Tutores: Dr. Yovani Marrero Ponce MSc. Arelys López Sacerio Lic. Gerardo Maikel Casañola Martín “Año 49 de la Revolución Cubana” Curso 2006-2007 PENSAMIENTO “For all flesh is as grass, and all the glory of man as the flower of grass. The grass withereth, and the flower thereof falleth away: But the word of the Lord endureth for ever.” 1 Peter1:24,25. “Todo carne es como hierba y toda la gloria del hombre como flor de la hierba; la hierba se seca y la flor se cae, mas la palabra del Señor permanece para siempre.” 1 Pedro 1:24,25. DEDICATORIA For all my friends and family, especially my daughter, Naarah Melani Nerissa Athanase and my husband, Jeremiah Wayn Athanase, with love and admiration. “I have fought a good fight, I have finished my course…” 2Tim 4:7. Con mucho cariño y admiración, a todas mis amigos y mi familia en particular a mi hija, Naarah Melani Nerissa Athanase y mi esposo, Jeremiah Wayn Athanase. “He peleada la buena batalla, he acabado la carrera…” 2Ti 4:7 AGRADECIMIENTOS For me it is an enormous pleasure to be able to express my sincere gratefulness to all those people that in one way or another has helped me to successfully culminate my studies and this work. I would especially like to thank God because without him I am nothing; to my family for their faith, support, love and patience; to my tutors especially Arelys for their attention, dedication and orientation during this work; to all the professors of the career that made possible with their patient, constant and opportune help my formation as a pharmaceutical professional; to my friends, in particular to Solange and Harun; to all thank you.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Theophylline-7-Acetic Acid

    Theophylline-7-Acetic Acid

    Theophylline-7-acetic acid sc-237085 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Theophylline-7-acetic acid STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C9-H10-N4-O4, "purine-7-acetic acid, 1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxo-", acefylline, acephylline, 7-(carboxymethyl)theophylline, "1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxopurine-7-acetic acid", "7-theophyllineacetic acid", "7-theophyllinylacetic acid", alkaloid Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 1 of 8 CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Xanthine derivatives may produce nausea, vomiting, anorexia, stomach pain, vomiting of blood and diarrhea. Protein in the urine, increased amounts of urine output, and increased excretion of renal tubular cells and red blood cells may also occur.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Bahrain-Pharma-1444108170.Pdf

    Bahrain-Pharma-1444108170.Pdf

    Fill Type of Competition S. No BP Brand Name Therapeutical Class Potency Generic Name/Composition Volume Dosage Name,company, retail price form Each 5 ml contents: Samol 120 ml Salbutamol Sulphate 2mg Salbutamol 1 Anti-Asthmatic agent (Bronchodilator) Each 5ml contains Acefylline piperazine 125mg Pifalin 100 ml Acefylline Piperazine 2 (125mg/5ml) Acefylline Piperazine 45mg, Diphenhydramine Dephicef 100 ml Acefylline Piperazine + Diphenhydramine 3 8mg/5ml Ammonium Chloride 100.00mg , Sodium Clomadrin 100 ml Citrate 60.00mg, Ephedrine HCl 7.00mg, Ammonium Chloride + Sodium Citrate + Ephedrine HCl + Chlorpheniramine Maleate 4 Chlorpheniramine Maleate 2.00mg/5ml Each 5 ml contents: Ambroxol HCl eq. to 100 ml Ambroxol 15mg 5 Ambrol Ambroxol HCl Each 5 ml contents: Ambroxol HCl eq. to Cough and Cold 100 ml Syrup 6 Ambroxol 30mg 7 Dextron 100 ml 15mg/5 ml Dextromethorphan Hbr 8 Gufosil 100 ml 100mg/5 ml Guaifenesin 9 Proligen 120 ml 1.25mg + 30mg/5 ml Triprolodin HCl + Pseudoephedrine HCl 10 Tripodil 120 ml 1.25mg + 30mg + 10mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr 11 Tripogin 120 ml 1.25mg + 30mg + 100 mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Guaifenesin 12 Dexotrin 120 ml 1.25mg +10mg + 7.5mg + 50mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr + Guaifenesin Wild cherry (Prunus serotina) + (myroxylon balsamum) + Mallow (Malva Sylvestris) + Welcosin 120 ml 60mg + 18.75mg + 7.5mg + 7.5mg / 5ml 13 Marshnallow (Althaea officinalis) 14 Ivosil 100 ml Each 5 ml contents: Ivy leaf 15 Hexobim 100 ml 4mg/5mlIvy leaves dried extract (4-8:1, 100%) 100 mg Bromhexine HCl Carbocisteine 2% and 5% (i.e.
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al

    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
  • (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski Et Al

    (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski Et Al

    US009687458B2 (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski et al. (45) Date of Patent: Jun. 27, 2017 (54) TRANS-CLOMIPHENE FOR USE IN 6,143,353 A 1 1/2000 Oshlack CANCER THERAPY 6,190,591 B1 2/2001 Van Lengerich 6,221,399 B1 4/2001 Rolfes 6,248,363 B1 6, 2001 Patel (71) Applicant: REPROS THERAPEUTICS INC., 6,291,505 B1 9/2001 Huebner et al. The Woodlands, TX (US) 6,342,250 B1 1/2002 Masters 6,391920 B1 5, 2002 Fisch (72) Inventors: Joseph S. Podolski. The Woodlands, 6,511.986 B2 1/2003 Zhang et al. TX (US); Ronald D. Wiehle, Houston, 826 R $398 Ma'al TX (US); Kuang Hsu, The Woodlands, 6,638,528s- ww. B1 10/2003 KaniosaO ( a. TX (US); Greg Fontenot, The 6,645,974 B2 11/2003 Hutchinson et al. Woodlands, TX (US) 6,653,297 B1 11/2003 Hodgen 6,685,957 B1 2/2004 Bezemer et al. (73) Assignee: Repros Therapeutics Inc., The $33. R: 3. ErSC Woodlands, TX (US) 7,105,679 B2 9/2006 Kanojia et al. 7,354,581 B2 4/2008 Cedarb tal. (*) Notice: Subject to any disclaimer, the term of this 7,799,782 B2 9/2010 T al patent is extended or adjusted under 35 8,247456 B2 8/2012 Podolski U.S.C. 154(b) by 0 days. 8,377,991 B2 2/2013 Van AS 2002/O1200 12 A1 8, 2002 Fisch (21) Appl. No.: 14/440,007 (Continued) (22) PCT Filed: Oct.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).